BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
5/8 — Partial
Priority Review
KEPIVANCE (palifermin) by Swedish Orphan Biovitrum is (fgf) family that binds to the kgf receptor. Approved for mucositis, head and neck cancer. First approved in 2004.
Drug data last refreshed 20h ago
Mechanism of Action
(FGF) family that binds to the KGF receptor. Binding of KGF to its receptor has been reported to result in proliferation, differentiation, and migration of epithelial cells. The KGF receptor, one of four receptors in the FGF family, has been reported to be present on epithelial cells in many…
Pharmacologic Class:
Mucocutaneous Epithelial Cell Growth Factor
Indications (2)
Worked on KEPIVANCE at Swedish Orphan Biovitrum? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.